{"id":"flucytosine","rwe":[{"pmid":"41884794","year":"2026","title":"Successful use of isavuconazole as secondary prophylaxis of cryptococcal meningitis in a person living with HIV and AIDS: a case report.","finding":"","journal":"Therapeutic advances in infectious disease","studyType":"Clinical Study"},{"pmid":"41879325","year":"2026","title":"Detecting healthcare-associated transmission and antifungal resistance in Candida auris via whole genome sequencing.","finding":"","journal":"Journal of clinical microbiology","studyType":"Clinical Study"},{"pmid":"41877274","year":"2026","title":"Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial.","finding":"","journal":"Trials","studyType":"Clinical Study"},{"pmid":"41869200","year":"2026","title":"Immunocompetent but Not Immune: A Prolonged Course of Cryptococcal Meningitis.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41841072","year":"2026","title":"Successful Long-Term Use of Isavuconazole in a Tacrolimus-Treated Japanese Kidney Transplant Recipient With Disseminated Cryptococcosis and Probable Invasive Aspergillosis.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"_fda":{"id":"f6d603f8-d4ee-4541-928a-eb81b26bd4db","set_id":"01d874f9-e073-4092-94ad-da361551d4bf","openfda":{"nui":["N0000175459","N0000175467"],"unii":["D83282DT06"],"route":["ORAL"],"rxcui":["197702","197703"],"spl_id":["f6d603f8-d4ee-4541-928a-eb81b26bd4db"],"brand_name":["Flucytosine"],"spl_set_id":["01d874f9-e073-4092-94ad-da361551d4bf"],"package_ndc":["0904-6834-07","0904-6835-07"],"product_ndc":["0904-6834","0904-6835"],"generic_name":["FLUCYTOSINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLUCYTOSINE"],"pharm_class_epc":["Nucleoside Analog Antifungal [EPC]"],"manufacturer_name":["Major Pharmaceuticals"],"application_number":["ANDA204652"],"original_packager_product_ndc":["43386-771","43386-770"]},"version":"7","warnings":["WARNINGS Flucytosine Capsules USP must be given with extreme caution to patients with impaired renal function. Since Flucytosine Capsules USP is excreted primarily by the kidneys, renal impairment may lead to accumulation of the drug. Flucytosine Capsules USP serum concentrations should be monitored to determine the adequacy of renal excretion in such patients. Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug. Flucytosine Capsules USP must be given with extreme caution to patients with bone marrow depression. Patients may be more prone to depression of bone marrow function if they: 1) have a hematologic disease, 2) are being treated with radiation or drugs which depress bone marrow, or 3) have a history of treatment with such drugs or radiation. Bone marrow toxicity can be irreversible and may lead to death in immunosuppressed patients. Frequent monitoring of hepatic function and of the hematopoietic system is indicated during therapy. 5-Fluorouracil is a metabolite of flucytosine. Dihydropyrimidine dehydrogenase is a key enzyme involved in the metabolism and elimination of 5-fluorouracil. Therefore, the risk of severe drug toxicity is increased when Flucytosine Capsules, USP is used in individuals with deficiency in DPD. Possible drug toxicities include mucositis, diarrhea, neutropenia, and neurotoxicity. Determination of DPD activity may be considered where drug toxicity is confirmed or suspected. In the event of suspected drug toxicity, consider stopping Flucytosine Capsules USP, treatment."],"pregnancy":["Pregnancy Teratogenic Effects Flucytosine was shown to be teratogenic (vertebral fusions) in the rat at doses of 40 mg/kg/day (298 mg/M 2 /day or 0.051 times the human dose) administered on days 7 to 13 of gestation. At higher doses (700 mg/kg/day; 5208 mg/M 2 /day or 0.89 times the human dose administered on days 9 to 12 of gestation), cleft lip and palate and micrognathia were reported. Flucytosine was not teratogenic in rabbits up to a dose of 100 mg/kg/day (1423 mg/M 2 /day or 0.243 times the human dose) administered on days 6 to 18 of gestation. In mice, 400 mg/kg/day of flucytosine (1380 mg/M 2 /day or 0.236 times the human dose) administered on days 7 to 13 of gestation was associated with a low incidence of cleft palate that was not statistically significant. Studies in pregnant rats have shown that flucytosine injected intraperitoneally crosses the placental barrier. There are no adequate and well-controlled studies in pregnant women. Flucytosine Capsules USP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE There is no experience with intentional overdosage. It is reasonable to expect that overdosage may produce pronounced manifestations of the known clinical adverse reactions. Prolonged serum concentrations in excess of 100 mcg/mL may be associated with an increased incidence of toxicity, especially gastrointestinal (diarrhea, nausea, vomiting), hematologic (leukopenia, thrombocytopenia) and hepatic (hepatitis). In the management of overdosage, prompt gastric lavage or the use of an emetic is recommended. Adequate fluid intake should be maintained, by the intravenous route if necessary, since Flucytosine Capsules USP is excreted unchanged via the renal tract. The hematologic parameters should be monitored frequently; liver and kidney function should be carefully monitored. Should any abnormalities appear in any of these parameters, appropriate therapeutic measures should be instituted. Since hemodialysis has been shown to rapidly reduce serum concentrations in anuric patients, this method may be considered in the management of overdosage."],"description":["DESCRIPTION Flucytosine Capsules USP, an antifungal agent, is available as 250 mg and 500 mg capsules for oral administration. In addition to the active ingredient of flucytosine, each capsule contains lactose monohydrate, colloidal silicon dioxide, talc, sodium starch glycolate, magnesium stearate and hard gelatin capsule shell which contains gelatin, purified water, black iron oxide, FD&C Blue No.1, titanium dioxide and sodium lauryl sulfate for 250 mg strength; gelatin, purified water, black iron oxide and titanium dioxide for 500 mg strength. The imprinting ink contains black iron oxide, shellac, potassium hydroxide, titanium dioxide, povidone, sodium hydroxide and FD &C Red No. 40 aluminum lake for 250 mg and 500 mg strengths. Chemically, flucytosine is 5-fluorocytosine, a fluorinated pyrimidine which is related to fluorouracil and floxuridine. It is a white or almost white, crystalline powder with a molecular weight of 129.09 and the following structural formula: structural formula"],"precautions":["PRECAUTIONS General Before therapy with Flucytosine Capsules USP is instituted, electrolytes (because of hypokalemia) and the hematologic and renal status of the patient should be determined (see WARNINGS ). Close monitoring of the patient during therapy is essential. Laboratory Tests Since renal impairment can cause progressive accumulation of the drug, blood concentrations and kidney function should be monitored during therapy. Hematologic status (leukocyte and thrombocyte count) and liver function (alkaline phosphatase, SGOT and SGPT) should be determined at frequent intervals during treatment as indicated. Drug Interactions Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of Flucytosine Capsules USP by competitive inhibition. Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine. Drug/Laboratory Test Interactions Measurement of serum creatinine levels should be determined by the JaffÉ reaction, since Flucytosine Capsules USP does not interfere with the determination of creatinine values by this method. Most automated equipment for measurement of creatinine makes use of the JaffÉ reaction. Carcinogenesis, Mutagenesis, Impairment of Fertility Flucytosine has not undergone adequate animal testing to evaluate carcinogenic potential. The mutagenic potential of flucytosine was evaluated in Ames-type studies with five different mutants of S. typhimurium and no mutagenicity was detected in the presence or absence of activating enzymes. Flucytosine was nonmutagenic in three different repair assay systems (i.e., rec, uvr and pol). There have been no adequate trials in animals on the effects of flucytosine on fertility or reproductive performance. The fertility and reproductive performance of the offspring (F 1 generation) of mice treated with 100 mg/kg/day (345 mg/M 2 /day or 0.059 times the human dose), 200 mg/kg/day (690 mg/M 2 /day or 0.118 times the human dose) or 400 mg/kg/day (1380 mg/M 2 /day or 0.236 times the human dose) of flucytosine on days 7 to 13 of gestation was studied; the in uterotreatment had no adverse effect on the fertility or reproductive performance of the offspring. Pregnancy Teratogenic Effects Flucytosine was shown to be teratogenic (vertebral fusions) in the rat at doses of 40 mg/kg/day (298 mg/M 2 /day or 0.051 times the human dose) administered on days 7 to 13 of gestation. At higher doses (700 mg/kg/day; 5208 mg/M 2 /day or 0.89 times the human dose administered on days 9 to 12 of gestation), cleft lip and palate and micrognathia were reported. Flucytosine was not teratogenic in rabbits up to a dose of 100 mg/kg/day (1423 mg/M 2 /day or 0.243 times the human dose) administered on days 6 to 18 of gestation. In mice, 400 mg/kg/day of flucytosine (1380 mg/M 2 /day or 0.236 times the human dose) administered on days 7 to 13 of gestation was associated with a low incidence of cleft palate that was not statistically significant. Studies in pregnant rats have shown that flucytosine injected intraperitoneally crosses the placental barrier. There are no adequate and well-controlled studies in pregnant women. Flucytosine Capsules USP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Flucytosine Capsules USP, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use The efficacy and safety of Flucytosine Capsules USP have not been systematically studied in pediatric patients. A small number of neonates have been treated with 25 to 200 mg/kg/day of flucytosine, with and without the addition of amphotericin B, for systemic candidiasis. No unexpected adverse reactions were reported in these patients. It should be noted, however, that hypokalemia and acidemia were reported in one patient who received flucytosine in combination with amphotericin B, and anemia was observed in a second patient who received flucytosine alone. Transient thrombocytopenia was noted in two additional patients, one of whom also received amphotericin B."],"how_supplied":["HOW SUPPLIED Flucytosine Capsules USP, 250 mg are size 2 hard gelatin capsule with blue opaque cap and grey opaque body imprinted with \"NL771\" on the cap with black ink and \"250\" on the body with red ink filled with white to off white powder. Cartons of 30 capsules (6 capsules each blister pack x 5), NDC 0904-6834-07 Flucytosine Capsules USP, 500 mg are size 0 hard gelatin capsule with grey opaque cap and white opaque body imprinted \"NL770\" on the cap with black ink and \"500\" on the body with red ink, filled with white to off white powder. Cartons of 30 capsules (6 capsules each blister pack x 5), NDC 0904-6835-07 WARNING: These Unit Dose packages are not child resistant and are Intended for Institutional Use Only. Keep this and all drugs out of the reach of children. Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873 Manufactured for: Lupin Pharmaceuticals, Inc. Naples, FL 34108 Packaged and Distributed by: MAJOR® PHARMACEUTICALS Indianapolis, IN 46268 USA Refer to package label for Distributor's NDC Number SAP code: 276392 Rev: 10/2024 logo"],"microbiology":["MICROBIOLOGY Mechanism of Action Flucytosine is taken up by fungal organisms via the enzyme cytosine permease. Inside the fungal cell, flucytosine is rapidly converted to fluorouracil by the enzyme cytosine deaminase. Fluorouracil exerts its antifungal activity through the subsequent conversion into several active metabolites, which inhibit protein synthesis by being falsely incorporated into fungal RNA or interfere with the biosynthesis of fungal DNA through the inhibition of the enzyme thymidylate synthetase. Activity In Vitro Flucytosine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections. Candida albicans Cryptococcus neoformans Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see : https://www.fda.gov/STIC."],"boxed_warning":["WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of Flucytosine Capsules USP."],"pediatric_use":["Pediatric Use The efficacy and safety of Flucytosine Capsules USP have not been systematically studied in pediatric patients. A small number of neonates have been treated with 25 to 200 mg/kg/day of flucytosine, with and without the addition of amphotericin B, for systemic candidiasis. No unexpected adverse reactions were reported in these patients. It should be noted, however, that hypokalemia and acidemia were reported in one patient who received flucytosine in combination with amphotericin B, and anemia was observed in a second patient who received flucytosine alone. Transient thrombocytopenia was noted in two additional patients, one of whom also received amphotericin B."],"effective_time":"20260107","nursing_mothers":["Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Flucytosine Capsules USP, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests Since renal impairment can cause progressive accumulation of the drug, blood concentrations and kidney function should be monitored during therapy. Hematologic status (leukocyte and thrombocyte count) and liver function (alkaline phosphatase, SGOT and SGPT) should be determined at frequent intervals during treatment as indicated."],"adverse_reactions":["ADVERSE REACTIONS The adverse reactions which have occurred during treatment with Flucytosine Capsules USP are grouped according to organ system affected. Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction. Respiratory: Respiratory arrest, chest pain, dyspnea. Dermatologic: Rash, pruritus, urticaria, photosensitivity. Gastrointestinal: Nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients, hepatic dysfunction, jaundice, ulcerative colitis, enterocolitis, bilirubin elevation, increased hepatic enzymes. Genitourinary: Azotemia, creatinine and BUN elevation, crystalluria, renal failure. Hematologic: Anemia, agranulocytosis, aplastic anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, and fatal cases of bone marrow aplasia. Neurologic: Ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, pyrexia, vertigo, sedation, convulsions. Psychiatric: Confusion, hallucinations, psychosis. Miscellaneous: Fatigue, hypoglycemia, hypokalemia, weakness, allergic reactions, Lyell's syndrome. To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-866-403-7592 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Flucytosine Capsules, USP is contraindicated in patients with a known hypersensitivity to the drug. Flucytosine Capsules, USP is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (see WARNINGS )."],"drug_interactions":["Drug Interactions Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of Flucytosine Capsules USP by competitive inhibition. Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. Flucytosine Capsules USP is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous administration showed 78% to 89% absorption of the oral dose. Peak serum concentrations of 30 to 40 mcg/mL were reached within 2 hours of administration of a 2 g oral dose to normal subjects. Other studies revealed mean serum concentrations of approximately 70 to 80 mcg/mL 1 to 2 hours after a dose in patients with normal renal function receiving a 6-week regimen of flucytosine (150 mg/kg/day given in divided doses every 6 hours) in combination with amphotericin B. The half-life in the majority of healthy subjects ranged between 2.4 and 4.8 hours. Flucytosine is excreted via the kidneys by means of glomerular filtration without significant tubular reabsorption. More than 90% of the total radioactivity after oral administration was recovered in the urine as intact drug. Flucytosine is deaminated (probably by gut bacteria) to 5-fluorouracil. The area under the curve (AUC) ratio of 5-fluorouracil to flucytosine is 4%. Approximately 1% of the dose is present in the urine as the α-fluoro-β-ureido-propionic acid metabolite. A small portion of the dose is excreted in the feces. The half-life of flucytosine is prolonged in patients with renal insufficiency; the average half-life in nephrectomized or anuric patients was 85 hours (range: 29.9 to 250 hours). A linear correlation was found between the elimination rate constant of flucytosine and creatinine clearance. In vitro studies have shown that 2.9% to 4% of flucytosine is protein-bound over the range of therapeutic concentrations found in the blood. Flucytosine readily penetrates the blood-brain barrier, achieving clinically significant concentrations in cerebrospinal fluid. Pharmacokinetics in Pediatric Patients Limited data are available regarding the pharmacokinetics of Flucytosine Capsules USP administered to neonatal patients being treated for systemic candidiasis. After five days of continuous therapy, median peak levels in infants were 19.6 mcg/mL, 27.7 mcg/mL, and 83.9 mcg/mL at doses of 25 mg/kg (N=3), 50 mg/kg (N=4), and 100 mg/kg (N=3), respectively. Mean time to peak serum levels was of 2.5 ± 1.3 hours, similar to that observed in adult patients. A good deal of interindividual variability was noted, which did not correlate with gestational age. Some patients had serum levels > 100 mcg/mL, suggesting a need for drug level monitoring during therapy. In another study, serum concentrations were determined during flucytosine therapy in two patients (total assays performed =10). Median serum flucytosine concentrations at steady state were calculated to be 57 ± 10 mcg/mL (doses of 50 to 125 mg/kg/day, normalized to 25 mg/kg per dose for comparison). In three infants receiving flucytosine 25 mg/kg/day (four divided doses), a median flucytosine half-life of 7.4 hours was observed, approximately double that seen in adult patients. The concentration of flucytosine in the cerebrospinal fluid of one infant was 43 mcg/mL 3 hours after a 25 mg oral dose, and ranged from 20 to 67 mg/L in another neonate receiving oral doses of 120 to 150 mg/kg/day. MICROBIOLOGY Mechanism of Action Flucytosine is taken up by fungal organisms via the enzyme cytosine permease. Inside the fungal cell, flucytosine is rapidly converted to fluorouracil by the enzyme cytosine deaminase. Fluorouracil exerts its antifungal activity through the subsequent conversion into several active metabolites, which inhibit protein synthesis by being falsely incorporated into fungal RNA or interfere with the biosynthesis of fungal DNA through the inhibition of the enzyme thymidylate synthetase. Activity In Vitro Flucytosine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections. Candida albicans Cryptococcus neoformans Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see : https://www.fda.gov/STIC. Drug Resistance Flucytosine resistance may arise from a mutation of an enzyme necessary for the cellular uptake or metabolism of flucytosine or from an increased synthesis of pyrimidines, which compete with the active metabolites of flucytosine (fluorinated antimetabolites). Resistance to flucytosine has been shown to develop during monotherapy after prolonged exposure to the drug. Drug Combination Antifungal synergism between flucytosine and polyene antibiotics, particularly amphotericin B has been reported in vitro. Flucytosine Capsules USP is usually administered in combination with amphotericin B due to lack of cross-resistance and reported synergistic activity of both drugs."],"indications_and_usage":["INDICATIONS AND USAGE Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY )."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The usual dosage of Flucytosine Capsules USP is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15-minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see WARNINGS ). Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY )."],"spl_product_data_elements":["Flucytosine Flucytosine FLUCYTOSINE FLUCYTOSINE LACTOSE MONOHYDRATE SILICON DIOXIDE TALC SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE GELATIN, UNSPECIFIED WATER FERROSOFERRIC OXIDE FD&C BLUE NO. 1 TITANIUM DIOXIDE SODIUM LAURYL SULFATE SHELLAC POTASSIUM HYDROXIDE POVIDONE, UNSPECIFIED SODIUM HYDROXIDE FD&C RED NO. 40 ALUMINUM OXIDE Opaque Body Opaque Cap 250;NL771 Flucytosine Flucytosine FLUCYTOSINE FLUCYTOSINE LACTOSE MONOHYDRATE SILICON DIOXIDE TALC SODIUM STARCH GLYCOLATE TYPE A POTATO MAGNESIUM STEARATE GELATIN, UNSPECIFIED WATER FERROSOFERRIC OXIDE TITANIUM DIOXIDE SHELLAC POTASSIUM HYDROXIDE POVIDONE, UNSPECIFIED SODIUM HYDROXIDE FD&C RED NO. 40 ALUMINUM OXIDE Opaque Body Opaque Cap 500;NL770"],"package_label_principal_display_panel":["Package/Label Display Panel MAJOR® NDC 0904-6834-07 Unit Dose Flucytosine Capsules, USP 250 mg 30 CAPSULES (5 x 6) Rx only 250mg carton label","Package/Label Display Panel MAJOR® NDC 0904-6835-07 Unit Dose Flucytosine Capsules, USP 500 mg 30 CAPSULES (5 x 6) Rx only 500mg carton label"]},"tags":[{"label":"Nucleoside Analog Antifungal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"D01AE21","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Candidal Urinary Tract Infection","category":"indication"},{"label":"Synergy for Candida Infection","category":"indication"},{"label":"Synergy for Cryptococcal Infection","category":"indication"},{"label":"Systemic Candidiasis Treatment Adjunct","category":"indication"},{"label":"Systemic Cryptococcosis Treatment Adjunct","category":"indication"},{"label":"Bausch","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antifungal Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of Flucytosine Capsules USP."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"412 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"124 reports"},{"date":"","signal":"IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME","source":"FDA FAERS","actionTaken":"100 reports"},{"date":"","signal":"MENINGITIS CRYPTOCOCCAL","source":"FDA FAERS","actionTaken":"91 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"RENAL IMPAIRMENT","source":"FDA FAERS","actionTaken":"68 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"CRYPTOCOCCOSIS","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"DISSEMINATED CRYPTOCOCCOSIS","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"56 reports"}],"drugInteractions":[{"drug":"Cytosine arabinoside","severity":"major","mechanism":"competitive inhibition","management":"Avoid concurrent use of cytosine arabinoside with Flucytosine Capsules USP","clinicalEffect":"inactivation of the antifungal activity of Flucytosine Capsules USP"},{"drug":"Drugs which impair glomerular filtration","severity":"moderate","mechanism":"impairment of glomerular filtration","management":"Monitor flucytosine levels and adjust dosage as necessary","clinicalEffect":"prolongation of the biological half-life of flucytosine"}],"commonSideEffects":[{"effect":"Hepatic necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Renal failure","drugRate":"reported","severity":"unknown"},{"effect":"Bone marrow aplasia","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Acute hepatic injury","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic dysfunction","drugRate":"reported","severity":"unknown"},{"effect":"Jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Ulcerative colitis","drugRate":"reported","severity":"unknown"},{"effect":"Enterocolitis","drugRate":"reported","severity":"unknown"},{"effect":"Bilirubin elevation","drugRate":"reported","severity":"unknown"},{"effect":"Increased hepatic enzymes","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac arrest","drugRate":"reported","severity":"unknown"},{"effect":"Myocardial toxicity","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular dysfunction","drugRate":"reported","severity":"unknown"},{"effect":"Respiratory arrest","drugRate":"reported","severity":"unknown"},{"effect":"Chest pain","drugRate":"reported","severity":"unknown"},{"effect":"Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Photosensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Emesis","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Duodenal ulcer","drugRate":"reported","severity":"unknown"},{"effect":"Azotemia","drugRate":"reported","severity":"unknown"},{"effect":"Creatinine and BUN elevation","drugRate":"reported","severity":"unknown"}],"contraindications":["Flucytosine Capsules, USP is contraindicated in patients with a known hypersensitivity to the drug.","Flucytosine Capsules, USP is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency."],"specialPopulations":{"Pregnancy":"Flucytosine was shown to be teratogenic (vertebral fusions) in the rat at doses of 40 mg/kg/day (298 mg/m 2/day or 0.051 times the human dose) administered on days to 13 of gestation. At higher doses (700 mg/kg/day; 5208 mg/m 2/day or 0.89 times the human dose administered on days to 12 of gestation), cleft lip and palate and micrognathia were reported. Flucytosine was not teratogenic in rabbits up to dose of 100 mg/kg/day (1423 mg/m 2/day or 0.243 times the human dose.","Paediatric use":"The efficacy and safety of flucytosine has not been systematically studied in pediatric patients. small number of neonates have been treated with 25 to 200 mg/kg/day of flucytosine, with and without the addition of amphotericin B, for systemic candidiasis. No unexpected adverse reactions were reported in these patients. It should be noted, however, that hypokalemia and acidemia were reported in one patient who received flucytosine in combination with amphotericin B, and anemia was"}},"trials":[],"aliases":[],"company":"Bausch Health","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUCYTOSINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:39:28.198427+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:39:34.744143+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:39:26.805111+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUCYTOSINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:39:35.482944+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:25.376640+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:25.376807+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:19.648471+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of Flucytosine Capsules USP.","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:25.376825+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:39:36.973596+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thymidylate synthase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:36.066727+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:54.099825+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1463/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:39:35.957384+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:43.787596+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA204652","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:39:25.376836+00:00"}},"allNames":"ancobon","offLabel":[],"synonyms":["flucytosine","Ro-2-9915","Ro 2-9915","ancotil","ancobon","5-fluorocytosine"],"timeline":[{"date":"1971-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from VALEANT to Bausch"},{"date":"1971-11-26","type":"positive","source":"DrugCentral","milestone":"FDA approval (Valeant)"},{"date":"2020-04-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 5 manufacturers approved"}],"aiSummary":"Ancobon (Flucytosine) is a nucleoside analog antifungal medication developed by Valeant and currently owned by Bausch. It targets the 5-hydroxytryptamine receptor 2A and works by inhibiting fungal DNA synthesis. Ancobon is approved to treat various fungal infections, including candidal urinary tract infections and systemic cryptococcosis. The medication is available as a generic product, off-patent, and has a bioavailability of 84% with a half-life of 4.2 hours. Key safety considerations include monitoring for bone marrow suppression and hepatotoxicity.","approvals":[{"date":"1971-11-26","orphan":false,"company":"VALEANT","regulator":"FDA"}],"brandName":"Ancobon","ecosystem":[{"indication":"Candidal Urinary Tract Infection","otherDrugs":[{"name":"fluconazole","slug":"fluconazole","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Synergy for Candida Infection","otherDrugs":[],"globalPrevalence":null},{"indication":"Synergy for Cryptococcal Infection","otherDrugs":[],"globalPrevalence":null},{"indication":"Systemic Candidiasis Treatment Adjunct","otherDrugs":[],"globalPrevalence":null},{"indication":"Systemic Cryptococcosis Treatment Adjunct","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","novelty":"Follow-on","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"}],"modality":"Small Molecule","drugClass":"Nucleoside Analog Antifungal [EPC]","explanation":"","oneSentence":"","technicalDetail":"Ancobon is a prodrug that is converted into 5-fluorouracil (5-FU) by the fungal enzyme cytosine deaminase, which then acts as a thymidylate synthase inhibitor, disrupting DNA synthesis and leading to fungal cell death."},"commercial":{"launchDate":"1971","_launchSource":"DrugCentral (FDA 1971-11-26, VALEANT)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1188","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUCYTOSINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUCYTOSINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:30:05.883410","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:40:19.923230+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"undecylenic acid","drugSlug":"undecylenic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorphenesin carbamate","drugSlug":"chlorphenesin-carbamate","fdaApproval":"1965-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"haloprogin","drugSlug":"haloprogin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"selenium sulfide","drugSlug":"selenium-sulfide","fdaApproval":"1951-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclopirox","drugSlug":"ciclopirox","fdaApproval":"1982-12-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"terbinafine","drugSlug":"terbinafine","fdaApproval":"1992-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tolnaftate","drugSlug":"tolnaftate","fdaApproval":"","relationship":"same-class"},{"drugName":"naftifine","drugSlug":"naftifine","fdaApproval":"1988-02-29","patentExpiry":"Jan 31, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"butenafine","drugSlug":"butenafine","fdaApproval":"1996-10-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tavaborole","drugSlug":"tavaborole","fdaApproval":"2014-07-07","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"flucytosine","indications":{"approved":[{"id":"flucytosine-serious-candida-infections","name":"Serious Candida Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with serious infections caused by susceptible strains of Candida","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with serious infections caused by susceptible strains of Candida","diagnosticRequired":null,"brandNameForIndication":"Ancobon"},{"id":"flucytosine-candida-pulmonary-infections","name":"Candida Pulmonary Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pulmonary infections caused by susceptible strains of Candida","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pulmonary infections caused by susceptible strains of Candida","diagnosticRequired":null,"brandNameForIndication":"Ancobon"},{"id":"flucytosine-cryptococcus-meningitis","name":"Cryptococcus Meningitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with meningitis caused by susceptible strains of Cryptococcus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with meningitis caused by susceptible strains of Cryptococcus","diagnosticRequired":null,"brandNameForIndication":"Ancobon"},{"id":"flucytosine-cryptococcus-pulmonary-infecti","name":"Cryptococcus Pulmonary Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pulmonary infections caused by susceptible strains of Cryptococcus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pulmonary infections caused by susceptible strains of Cryptococcus","diagnosticRequired":null,"brandNameForIndication":"Ancobon"},{"id":"flucytosine-cryptococcus-septicemia","name":"Cryptococcus Septicemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with septicemia caused by susceptible strains of Cryptococcus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with septicemia caused by susceptible strains of Cryptococcus","diagnosticRequired":null,"brandNameForIndication":"Ancobon"},{"id":"flucytosine-cryptococcus-urinary-tract-inf","name":"Cryptococcus Urinary Tract Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with urinary tract infections caused by susceptible strains of Cryptococcus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with urinary tract infections caused by susceptible strains of Cryptococcus","diagnosticRequired":null,"brandNameForIndication":"Ancobon"}],"offLabel":[{"name":"Chromoblastomycosis","source":"DrugCentral","drugName":"FLUCYTOSINE"}],"pipeline":[]},"currentOwner":"Bausch","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"undecylenic-acid","brandName":"undecylenic acid","genericName":"undecylenic acid","approvalYear":"","relationship":"same-class"},{"drugId":"chlorphenesin-carbamate","brandName":"chlorphenesin carbamate","genericName":"chlorphenesin carbamate","approvalYear":"1965","relationship":"same-class"},{"drugId":"haloprogin","brandName":"haloprogin","genericName":"haloprogin","approvalYear":"","relationship":"same-class"},{"drugId":"selenium-sulfide","brandName":"selenium sulfide","genericName":"selenium sulfide","approvalYear":"1951","relationship":"same-class"},{"drugId":"ciclopirox","brandName":"ciclopirox","genericName":"ciclopirox","approvalYear":"1982","relationship":"same-class"},{"drugId":"terbinafine","brandName":"terbinafine","genericName":"terbinafine","approvalYear":"1992","relationship":"same-class"},{"drugId":"tolnaftate","brandName":"tolnaftate","genericName":"tolnaftate","approvalYear":"","relationship":"same-class"},{"drugId":"naftifine","brandName":"naftifine","genericName":"naftifine","approvalYear":"1988","relationship":"same-class"},{"drugId":"butenafine","brandName":"butenafine","genericName":"butenafine","approvalYear":"1996","relationship":"same-class"},{"drugId":"tavaborole","brandName":"tavaborole","genericName":"tavaborole","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06504381","phase":"PHASE1,PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":["High Grade Glioma","MGMT-Unmethylated Glioblastoma","MGMT-Methylated Glioblastoma"],"enrollment":70,"completionDate":"2042-01-31"},{"nctId":"NCT06666322","phase":"PHASE2,PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":["Hiv","Cryptococcal Meningitis"],"enrollment":2000,"completionDate":"2032-04-21"},{"nctId":"NCT06525389","phase":"PHASE3","title":"Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-04-01","conditions":["Talaromycosis"],"enrollment":428,"completionDate":"2031-11-01"},{"nctId":"NCT06414512","phase":"PHASE2","title":"Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2024-04-09","conditions":["Cryptococcal Meningitis"],"enrollment":48,"completionDate":"2024-10-02"},{"nctId":"NCT06264388","phase":"PHASE2","title":"DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma","status":"RECRUITING","sponsor":"Ashish Shah","startDate":"2024-05-01","conditions":["High Grade Glioma","Anaplastic Astrocytoma"],"enrollment":33,"completionDate":"2034-05-01"},{"nctId":"NCT06562621","phase":"PHASE1,PHASE2","title":"Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Beijing Neurosurgical Institute","startDate":"2018-08-01","conditions":["Glioblastoma Multiforme","Gliomas, Malignant"],"enrollment":38,"completionDate":"2024-03-01"},{"nctId":"NCT06178627","phase":"PHASE4","title":"Amphotericin B for Non-HIV Cryptococcal Meningitis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Huashan Hospital","startDate":"2023-08-13","conditions":["Cryptococcal Meningitis","Antifungal Agents"],"enrollment":250,"completionDate":"2026-08-31"},{"nctId":"NCT04194034","phase":"PHASE1,PHASE2","title":"Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2020-01-17","conditions":["Colorectal Neoplasms"],"enrollment":15,"completionDate":"2023-02-23"},{"nctId":"NCT03724071","phase":"PHASE1,PHASE2","title":"Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.","status":"TERMINATED","sponsor":"Transgene","startDate":"2018-10-16","conditions":["Colorectal Neoplasm","Digestive System Neoplasm"],"enrollment":51,"completionDate":"2023-02-23"},{"nctId":"NCT04657315","phase":"PHASE1,PHASE2","title":"Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients","status":"COMPLETED","sponsor":"CHA University","startDate":"2020-06-24","conditions":["Glioblastoma","Adult Gliosarcoma","Neoplasms, Brain","Neoplasms, Germ Cell and Embryonal","Recurrent Glioblastoma"],"enrollment":10,"completionDate":"2022-12-22"},{"nctId":"NCT05541107","phase":"PHASE3","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3","status":"UNKNOWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2023-01","conditions":["Cryptococcal Meningitis"],"enrollment":270,"completionDate":"2025-01"},{"nctId":"NCT05471063","phase":"NA","title":"Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-08-22","conditions":["Cryptococcal Meningitis"],"enrollment":30,"completionDate":"2023-04-30"},{"nctId":"NCT04532463","phase":"","title":"Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Pharmacy, Yangon","startDate":"2020-10-01","conditions":["Cryptococcal Meningitis"],"enrollment":30,"completionDate":"2022-04-20"},{"nctId":"NCT03281382","phase":"PHASE1","title":"Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2017-07-01","conditions":["Metastatic Pancreatic Cancer"],"enrollment":12,"completionDate":"2019-05-28"},{"nctId":"NCT00000639","phase":"NA","title":"A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":400,"completionDate":"1997-09"},{"nctId":"NCT00000776","phase":"PHASE2","title":"Dexamethasone in Cryptococcal Meningitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":36,"completionDate":"1996-09"},{"nctId":"NCT02015819","phase":"PHASE1","title":"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2014-10-07","conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Tumor","Anaplastic Oligoastrocytoma"],"enrollment":16,"completionDate":"2017-10-07"},{"nctId":"NCT01562132","phase":"PHASE2","title":"Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection","status":"TERMINATED","sponsor":"Yale University","startDate":"2013-09","conditions":["Cryptococcal Infection Disseminated"],"enrollment":6,"completionDate":"2014-07"},{"nctId":"NCT01562626","phase":"PHASE1,PHASE2","title":"Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors","status":"SUSPENDED","sponsor":"Anaeropharma Science, Inc.","startDate":"2012-09","conditions":["Tumors","Neoplasms","Cancer"],"enrollment":75,"completionDate":"2021-05"},{"nctId":"NCT04072640","phase":"EARLY_PHASE1","title":"Three Induction Treatments on Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-01-25","conditions":["Cryptococcal Meningitis","HIV/AIDS"],"enrollment":120,"completionDate":"2022-12-01"},{"nctId":"NCT04226066","phase":"PHASE1,PHASE2","title":"Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Tasly Tianjin Biopharmaceutical Co., Ltd.","startDate":"2019-11-20","conditions":["Advanced Malignant Solid Tumors"],"enrollment":69,"completionDate":"2022-05-31"},{"nctId":"NCT04195373","phase":"PHASE1","title":"A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract","status":"WITHDRAWN","sponsor":"Themis Bioscience GmbH","startDate":"2020-11-23","conditions":["Gastrointestinal Cancer"],"enrollment":0,"completionDate":"2020-11-23"},{"nctId":"NCT04327011","phase":"PHASE1","title":"A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2011-02","conditions":["Glioblastoma Multiforme","Astrocytoma","Gliomas, Malignant"],"enrollment":65,"completionDate":"2019-12"},{"nctId":"NCT04089163","phase":"PHASE1","title":"A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)","status":"WITHDRAWN","sponsor":"Tocagen Inc.","startDate":"2019-12","conditions":["Bladder Cancer"],"enrollment":0,"completionDate":"2027-01"},{"nctId":"NCT02598011","phase":"PHASE1","title":"A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care","status":"WITHDRAWN","sponsor":"Tocagen Inc.","startDate":"2017-01","conditions":["Newly Diagnosed High Grade Glioma (HGG)"],"enrollment":0,"completionDate":""},{"nctId":"NCT04105374","phase":"PHASE2,PHASE3","title":"Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma","status":"WITHDRAWN","sponsor":"NRG Oncology","startDate":"2020-01-31","conditions":["Anaplastic Astrocytoma","Glioblastoma","Oligodendroglioma","Supratentorial Glioblastoma"],"enrollment":0,"completionDate":"2030-11-30"},{"nctId":"NCT02576665","phase":"PHASE1","title":"A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2016-07","conditions":["Colorectal Cancer","Triple Negative Breast Cancer","Pancreatic Cancer","Non-Small Cell Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Lymphoma","Sarcoma","Bladder Cancer","Melanoma","IDH1 Mutated Solid Tumors","IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)"],"enrollment":21,"completionDate":"2019-12-20"},{"nctId":"NCT02414165","phase":"PHASE2,PHASE3","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","status":"TERMINATED","sponsor":"Tocagen Inc.","startDate":"2015-11-30","conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma"],"enrollment":403,"completionDate":"2019-12-20"},{"nctId":"NCT04140461","phase":"PHASE3","title":"AmB Dose for Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2020-01-02","conditions":["Cryptococcal Meningitis","HIV Infections"],"enrollment":40,"completionDate":"2022-04-30"},{"nctId":"NCT03029871","phase":"PHASE1","title":"Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer","status":"WITHDRAWN","sponsor":"Benjamin Movsas, M.D.","startDate":"2017-01-13","conditions":["Non-small Cell Lung Cancer Stage I"],"enrollment":0,"completionDate":"2022-12-31"},{"nctId":"NCT01156584","phase":"PHASE1","title":"A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Tocagen Inc.","startDate":"2010-07","conditions":["Glioblastoma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma"],"enrollment":54,"completionDate":"2016-08-18"},{"nctId":"NCT01985256","phase":"PHASE1","title":"Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor","status":"COMPLETED","sponsor":"Tocagen Inc.","startDate":"2014-02","conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma"],"enrollment":17,"completionDate":"2016-03-03"},{"nctId":"NCT01470794","phase":"PHASE1","title":"Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor","status":"COMPLETED","sponsor":"Tocagen Inc.","startDate":"2012-02","conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma"],"enrollment":58,"completionDate":"2016-04-12"},{"nctId":"NCT01172964","phase":"PHASE1","title":"A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2010-08","conditions":["Adult Anaplastic Astrocytoma","Recurrent Grade III Glioma","Recurrent Grade IV Glioma","Adult Anaplastic Oligodendroglioma","Adult Brain Tumor","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Recurrent Adult Brain Tumor","Adult Anaplastic Oligoastrocytoma","Recurrent High Grade Glioma"],"enrollment":15,"completionDate":"2015-02-11"},{"nctId":"NCT03294486","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-10-12","conditions":["Glioblastoma","Brain Cancer"],"enrollment":78,"completionDate":"2021-09"},{"nctId":"NCT01526213","phase":"NA","title":"Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-09","conditions":["Food-drug Interaction"],"enrollment":18,"completionDate":"2011-04"},{"nctId":"NCT01715922","phase":"PHASE2,PHASE3","title":"Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-05","conditions":["Cryptococcal Meningitis","HIV"],"enrollment":41,"completionDate":"2016-09"},{"nctId":"NCT00583492","phase":"PHASE2","title":"Randomized Trial of Suicide Gene Therapy and Prostate Cancer","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2007-12","conditions":["Prostate Cancer"],"enrollment":44,"completionDate":"2013-09"},{"nctId":"NCT00978107","phase":"PHASE1","title":"Trial of TG4023 Combined With Flucytosine in Liver Tumors","status":"COMPLETED","sponsor":"Transgene","startDate":"2009-09","conditions":["Hepatocellular Carcinoma"],"enrollment":16,"completionDate":"2011-09"},{"nctId":"NCT02136030","phase":"NA","title":"Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"TTY Biopharm","startDate":"2011-02","conditions":["Cryptococcal Meningitis"],"enrollment":84,"completionDate":"2016-12"},{"nctId":"NCT00415454","phase":"PHASE1","title":"Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2006-11","conditions":["Pancreatic Cancer"],"enrollment":8,"completionDate":""},{"nctId":"NCT00000708","phase":"NA","title":"Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":120,"completionDate":""},{"nctId":"NCT00012467","phase":"PHASE2","title":"Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis","status":"COMPLETED","sponsor":"InterMune","startDate":"2000-01","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":60,"completionDate":"2001-07"},{"nctId":"NCT00847678","phase":"PHASE2","title":"Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-08","conditions":["Cryptococcal Meningitis"],"enrollment":38,"completionDate":""},{"nctId":"NCT00002075","phase":"NA","title":"Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002113","phase":"NA","title":"A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":64,"completionDate":""},{"nctId":"NCT00002068","phase":"NA","title":"A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002305","phase":"NA","title":"A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":["Meningitis, Cryptococcal","HIV Infections"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"FLUCYTOSINE"},{"form":"CAPSULE","route":"ORAL","productName":"Flucytosine"},{"form":"CAPSULE","route":"ORAL","productName":"flucytosine"},{"form":"CAPSULE","route":"ORAL","productName":"ANCOBON"},{"form":"CAPSULE","route":"ORAL","productName":"Flucytosine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146153","MMSL":"186215","NDDF":"002898","UNII":"D83282DT06","VUID":"4017792","CHEBI":"CHEBI:5100","VANDF":"4017792","INN_ID":"2729","RXNORM":"227633","UMLSCUI":"C0016278","chemblId":"CHEMBL1463","ChEMBL_ID":"CHEMBL1463","KEGG_DRUG":"D00323","DRUGBANK_ID":"DB01099","PDB_CHEM_ID":" 1LD","PUBCHEM_CID":"3366","SNOMEDCT_US":"28506006","MESH_DESCRIPTOR_UI":"D005437"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1971-","companyName":"Valeant","relationship":"Original Developer"},{"period":"present","companyName":"Bausch","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.2 hours","clearance":"2.0 mL/min/kg","bioavailability":"84%","fractionUnbound":"1.0%","volumeOfDistribution":"0.68 L/kg"},"publicationCount":2378,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"D01AE21","allCodes":["D01AE21","J02AX01"]},"biosimilarFilings":[],"originalDeveloper":"Valeant","recentPublications":[{"date":"2026 Jan-Dec","pmid":"41884794","title":"Successful use of isavuconazole as secondary prophylaxis of cryptococcal meningitis in a person living with HIV and AIDS: a case report.","journal":"Therapeutic advances in infectious disease"},{"date":"2026 Mar 25","pmid":"41879325","title":"Detecting healthcare-associated transmission and antifungal resistance in Candida auris via whole genome sequencing.","journal":"Journal of clinical microbiology"},{"date":"2026 Mar 24","pmid":"41877274","title":"Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial.","journal":"Trials"},{"date":"2026 Feb","pmid":"41869200","title":"Immunocompetent but Not Immune: A Prolonged Course of Cryptococcal Meningitis.","journal":"Cureus"},{"date":"2026 Feb","pmid":"41841072","title":"Successful Long-Term Use of Isavuconazole in a Tacrolimus-Treated Japanese Kidney Transplant Recipient With Disseminated Cryptococcosis and Probable Invasive Aspergillosis.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Aurobindo Pharma Ltd","Hikma","Laurus","Novel Labs Inc","Sigmapharm Labs Llc","Strides Pharma"],"status":"approved","companyName":"Bausch","companyId":"bausch","modality":"Small molecule","firstApprovalDate":"1971","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1971-11-26T00:00:00.000Z","mah":"VALEANT","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-01-08T00:00:00.000Z","mah":"BAUSCH","brand_name_local":null,"application_number":"NDA017001"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-07-07T00:00:00.000Z","mah":"NOVEL LABS INC","brand_name_local":null,"application_number":"ANDA204652"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-05-01T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":null,"application_number":"ANDA213665"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-01-09T00:00:00.000Z","mah":"STRIDES PHARMA","brand_name_local":null,"application_number":"ANDA212632"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-07-23T00:00:00.000Z","mah":"LAURUS","brand_name_local":null,"application_number":"ANDA218005"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:40:19.923230+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}